NCT04857827View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of QLS-101 in NTG

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions
Normal Tension Glaucoma (NTG)
Interventions
DRUG

QLS-101

Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.

DRUG

Timolol maleate PF 0.5% ophthalmic solution

Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.

Trial Locations (1)

57108

Vance Thompson Vision, Sioux Falls

All Listed Sponsors
lead

Qlaris Bio, Inc.

INDUSTRY

NCT04857827 - A Study to Evaluate Safety and Tolerability of QLS-101 in NTG | Biotech Hunter | Biotech Hunter